ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck
Part of paid clinical trials in Cleveland, Ohio.
- Sponsor
- Case Comprehensive Cancer Center
- Study ID
- NCT06357858
- Phase
- PHASE1
- Status
- Withdrawn
Conditions
- Head and Neck Squamous Cell Carcinoma
- Metastatic Squamous Cell Carcinoma
- Recurrent Squamous Cell Carcinoma of the Head and Neck
Eligibility Criteria
- Sex
- ALL
- Age
- 19 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- INQOVI (decitabine and cedazuridine) — DRUGOral decitabine (ASTX727) will be administered during D1-5 (DL1) or D1-4 (DL1-1).
- Nivolumab — DRUGNivolumab will be administered on D8 with every 4 week cycle.
Study Details
The goal of this clinical trial is to see if the combination of experimental drug ASTX727 and Nivolumab enhances the antitumor immune response in participants will recurrent or metastatic squamous cell carcinoma of the head and neck. Participants will take a pill called ASTX727 for 4 or 5 days every month followed by an injection of Nivolumab one week after the first dose of study medication.
Key Dates
- Start date
- Jun 1, 2024
- Status verified
- Jul 2024
- Primary completion
- Feb 28, 2025
- Completion
- Feb 28, 2026
Study Design
- Enrollment
- 0 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Oral Decitabine + NivolumabOral decitabine (ASTX727) will be administered during D1-5 (DL1) or D1-4 (DL1-1) followed by Nivolumab on D8 with every 4 week cycle. The expected minimum treatment cycle is 2 and maximum treatment cycle of 6. However, treatment can be continued until disease progression.
Primary Outcome Measure
Pharmacodynamics Effect of ASTX727 on global DNA methylation status [ Time Frame: 12 months after completion of treatment ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center | Cleveland | Ohio | 44106 | - |
Find similar trials in Cleveland, OH
By condition
Related Studies
- Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone SurgeryPHASE2 · Recruiting · ECOG-ACRIN Cancer Research Group · Birmingham, Alabama
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · Merus B.V. · La Jolla, California
- VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaPHASE1/PHASE2 · Recruiting · VM Oncology, LLC · Santa Rosa, California
- Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer PatientsPHASE2 · Recruiting · Vyriad, Inc. · Phoenix, Arizona